



## Targeting HIV Gag p24 to DICR on dendritic cells induces T cell and potent and long-lasting antibody responses in non-human primates

Anne-Laure Flamar, Roger Le Grand, Vanessa Contreras, Sandra Zurawski, Nathalie Dereuddre-Bosquet, Isabelle Mangeot, Frédéric Martinon, Sangkon Oh, Jacques Banchereau, Gérard Zurawski, et al.

### ► To cite this version:

Anne-Laure Flamar, Roger Le Grand, Vanessa Contreras, Sandra Zurawski, Nathalie Dereuddre-Bosquet, et al.. Targeting HIV Gag p24 to DICR on dendritic cells induces T cell and potent and long-lasting antibody responses in non-human primates. *Retrovirology*, 2012, 9 (Suppl 2), pp.P358. inserm-00731781


**HAL Id: inserm-00731781**

**<https://inserm.hal.science/inserm-00731781>**

Submitted on 13 Sep 2012

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



POSTER PRESENTATION

Open Access

# Targeting HIV Gag p24 to DCIR on dendritic cells induces T cell and potent and long-lasting antibody responses in non-human primates

A Flamar<sup>1\*</sup>, R Le Grand<sup>2</sup>, V Contreras<sup>2</sup>, S Zurawski<sup>1</sup>, N Dereuddre-Bosquet<sup>2</sup>, I Mangeot<sup>2</sup>, F Martinon<sup>2</sup>, S Oh<sup>1</sup>, J Banchereau<sup>1</sup>, G Zurawski<sup>1</sup>, Y Levy<sup>3</sup>

From AIDS Vaccine 2012

Boston, MA, USA. 9-12 September 2012

## Background

Targeting Dendritic Cells (DCs) with anti-DC receptor antibody-antigen fusion proteins is a novel approach in vaccine development for inducing potent humoral and cellular immune responses.

## Methods

We engineered an anti-human DCIR recombinant antibody cross-reacting with the cynomolgus macaque receptor fused via the heavy chain C-terminus to HIV-1 Gagp24 protein (anti-DCIR.Gagp24). HIV patient PBMC cultures were incubated with anti-DCIR and control hIgG4.Gagp24 fusion proteins. After 10 days, the total T cells were challenged with HIV Gagp24 peptide pools, and then antigen-specific cytokine production was detected using intracellular staining. Macaques were also immunized i.d. 3 times with anti-DCIR.Gagp24 or control hIgG4.Gagp24 with or without polyI:C. Gagp24-specific IgG titers from serum were measured by ELISA and the magnitude of the antigen-specific IFN $\gamma$  responses was assessed by ELISPOT.

## Results

In vitro, low doses of anti-DCIR Gagp24 prototype vaccine, but not the control hIgG4.Gagp24, expand of Gagp24-specific T cells. These in vitro-expanded antigen-specific T cells were multifunctional, simultaneously producing multiple cytokines (IFN $\gamma$ , TNF $\alpha$  and MIP-1 $\beta$ ). In vivo, in non-adjuvanted naïve animals, serum anti-Gagp24 antibodies were detectable 2 weeks after priming and titers were substantially increased after the 1st and

the 2nd boost with anti-DCIR.Gagp24 and were durable, while in the control hIgG4.Gagp24 group the responses were minimal. Poly I:C increased the magnitude of the responses in the anti-DCIR.Gagp24 and hIgG4.Gagp24 groups to a similar level in both groups. T cell responses induced by anti-DCIR Gagp24 could be enhanced after priming with a recombinant modified vaccinia virus Ankara (MVA) encoding HIV Gag/Pol/Nef. Boosting with anti-DCIR.Gagp24 plus poly I:C generated high titers of anti-Gagp24 antibody titers and strongly enhanced IFN $\gamma$ -producing T cells following priming with MVA HIV Gag/Pol/Nef.

## Conclusion

Our results demonstrate that heterologous prime-boost immunization with vectors and DC-targeting protein-based vaccines is a promising vaccination approach to optimize humoral and cellular immunity for therapeutic and preventive applications against AIDS.

## Author details

<sup>1</sup>Baylor Institute for Immunology Research, Dallas, TX, USA. <sup>2</sup>CEA, Fontenay-aux-Roses, France. <sup>3</sup>INSERM U955, Faculté de Médecine de Créteil, Créteil, France.

Published: 13 September 2012

doi:10.1186/1742-4690-9-S2-P358

**Cite this article as:** Flamar *et al.*: Targeting HIV Gag p24 to DCIR on dendritic cells induces T cell and potent and long-lasting antibody responses in non-human primates. *Retrovirology* 2012 **9**(Suppl 2):P358.

<sup>1</sup>Baylor Institute for Immunology Research, Dallas, TX, USA  
Full list of author information is available at the end of the article